444
Participants
Start Date
January 31, 2013
Primary Completion Date
October 31, 2014
Study Completion Date
October 31, 2014
Peginterferon Lambda-1a
Peginterferon Alfa-2a
Ribavirin
Daclatasvir
Telaprevir
Local Institution, Taipei
Local Institution, Taipei
Local Institution, Taoyuan District
Local Institution, Taichung
Local Institution, Tainan City
Local Institution, Buenos Aires
Local Institution, Buenos Aires
Local Institution, Prov de Santa Fe
Weill Cornell Medical College, New York
Premier Medical Group Of The Hudson Valley, Pc, Poughkeepsie
Local Institution, Zafed
Local Institution, Berlin
Lehigh Valley Health Network, Allentown
Local Institution, Hamburg
Local Institution, Pavia
Local Institution, Madrid
Gastrointestinal Specialists Of Georgia Pc, Marietta
Local Institution, Haifa
Nashville Medical Research Institute, Nashville
Local Institution, Grenoble
Local Institution, Santander
Local Institution, Modena
Local Institution, Essen
Local Institution, Zaragoza
Local Institution, Tel Litwinsky
Local Institution, Pisa
Local Institution, Tel Aviv
Local Institution, Mannheim
Local Institution, Foggia
Texas Clinical Research Institute, Llc, Arlington
Medvamc, Houston
Local Institution, Kaohsiung
Local Institution, München
Va Long Beach Healthcare System, Long Beach
Local Institution, Clichy
Local Institution, Villejuif
Local Institution, Messina
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Stavropol
Local Institution, Minato-ku
Local Institution, Sumida-ku
Local Institution, Musashino-shi
Local Institution, Kawasaki-shi
Local Institution, Yokohama
Local Institution, Yokohama
Local Institution, Higashiibaraki-gun
Local Institution, Nagoya
Local Institution, Gifu
Local Institution, Kyoto
Local Institution, Kyoto
Local Institution, Tanabe-shi
Local Institution, Kobe
Local Institution, Hiroshima
Local Institution, Kitakyushu-shi
Local Institution, Kitakyushu
Local Institution, Saga
Local Institution, Kumamoto
Local Institution, Buenos Aires
Local Institution, Capital Federal
Local Institution, Mar del Plata
Local Institution, Sapporo
Local Institution, Bialystok
Local Institution, Lodz
Local Institution, Mysłowice
Local Institution, Wroclaw
Local Institution, Busan
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Barcelona
Local Institution, London
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY